Your gateway to a free society
Article

Market Valuation: Expensive CAPE Or Cheap PEG?

Market Valuation: Expensive CAPE Or Cheap PEG? Authored by Michael Lebowitz via RealInvestmentAdvice.com, The S&P 500’s Shiller CAPE ratio just hit 41. Since 1881, the market valuation has been more expensive under CAPE only once. That was during the final months of the dot-com bubble. At the same time the CAPE is ringing warning bells, the PEG ratio, which measures price relative to expected earnings growth, is at its lowest level in at least three decades, possibly its cheapest reading ever. One market valuation says run for cover while another says bargain....
Back

aboutLiberty Portal

Liberty Portal is your gateway for free markets and free thinking. We aggregate open-sourced content to promote and popularize important people and lessons within the liberty movement.
suggested
Jun 11, 2026 / Tyler Durden
ActBlue CEO Pleads The Fifth During House Panel Hearing
Jul 14, 2026 / Tyler Durden
De-Banked: It's Only A Matter Of Time Before It Happens To You
De-Banked: It's Only A Matter Of Time Before It Happens To You Via InternationalMan.com, "We are writing to inform you that we cannot continue serving you. As a result of this decision, your account will be closed within 14 days from the date of this letter. Any remaining account balances will be sent by check to the address we have on file." Sooner or later, expect your bank to send you a letter like this. They won't even tell you why they are closing your account, and you will probably have trouble opening accounts at...
Read more
Jun 2, 2026 / Tyler Durden
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazimod doses meeting the primary endpoint at week 44. Clinical remission rates were 50.8% for the 25 mg dose...
Read more

support

If you like what we do and want to support us, then you are a fine humanitarian. Click the link below to find out more.

Support the liberty movement